Copyright © 2021 Pharmascimed. All Rights Reserved.
NICE
NICE gives Roche’s Perjeta nod for breast cancer
- February 18, 2019
- 0
Roche has bagged NICE backing for Perjeta (pertuxumab) in the prevention of early-stage HER2-positive breast cancer from recurring after surgery, after three attempts. The new draft guidance permits Perjeta to be given...
Read more
NICE rejects Novartis’ migraine drug for routine use
- January 9, 2019
- 0
The National Institute for Health Care and Excellent (NICE) has rejected Novartis' migraine drug Aimovig (erenumab) as preventative treatment for migraine in draft guidelines. The news comes after Aimovig was...
Read more